Antimicrobial Combinations, CF Panel

Test Code

16406

CPT Codes
87181 (x34)

Includes

Piperacillin and Tobramycin; Tobramycin and Meropenem; Tobramycin and Ceftazidime; Tobramycin and Ticar/Clav; Tobramycin and Imipenem; Tobramycin and Aztreonam; Meropenem and Amikacin; Imipenem and Ciprofloxacin; Ceftazidime and Amikacin; Meropenem and Ciprofloxacin; Piperacillin and Ciprofloxacin; Cefepime and Tobramycin

Preferred Specimen

Pure isolate of Pseudomonas aeruginosa on a slant or transport swab

Transport Temperature

Room temperature

Specimen Stability

Room temperature: Determined by viability
Refrigerated: Determined by viability
Frozen: Unacceptable

Methodology
Antibiotic Gradient

FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Setup Schedule

Sets up 7 days a week.

Report Available

Reports in 4 to 6 days.

Clinical Significance

The use of antimicrobial combinations for the treatment of infectious diseases has become more common due to several factors including: more severe infections, development of organism resistance, and infection with multiple organisms. Antimicrobial combinations may help to expand the spectrum of coverage, minimize drug toxicity, minimize development of resistance, and may lead to antimicrobial combination synergy.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Any Profile/panel component may be ordered separately. Reflex tests are performed at an additional charge.